Overview

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety and efficacy of a reduced intensity conditioning regimen during a double umbilical cord blood unit transplant with one of the cord blood units modulated with ProHema.
Phase:
Phase 1
Details
Lead Sponsor:
Fate Therapeutics
Collaborator:
Dana-Farber Cancer Institute
Treatments:
Antilymphocyte Serum
Fludarabine
Melphalan
Sirolimus
Tacrolimus